By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting originating in Anhui, People's Republic of China, by NewsRx journalists, research stated, "Accumulating evidence suggests a tumor suppressive role for miR-34a in human carcinogenesis. However, its precise biological role remains largely elusive."
The news reporters obtained a quote from the research from Anhui Medical University, "This study aimed to reveal the association of the miR-34a expression and its modulation of sensitivity to cisplatin in muscle-invasive bladder cancer (MIBC). miR-34a expression in MIBC cell lines and patient tissues was investigated using qPCR. The methylation analysis of miR-34a promoter region was performed by MassARRAY. Synthetic short single or double stranded RNA oligonucleotides and lentiviral vector were used to regulate miR-34a expression in MIBC cells to investigate its function in vitro and in vivo. miR-34a expression was frequently decreased in MIBC tissues and cell lines through promoter hypermethylation while it was epigenetically increased in MIBC cells following cisplatin treatment. Increased miR-34a expression significantly sensitized MIBC cells to cisplatin and inhibited the tumorigenicity and proliferation of cancer cells in vitro and in vivo. Furthermore, we identified CD44 as being targeted by miR-34a in MIBC cells following cisplatin treatment, and increased CD44 expression could efficiently reverse the effect of miR-34a on MIBC cell proliferation, colongenic potential and chemosensitivity."
According to the news reporters, the research concluded: "Cisplatin-based chemotherapy induced demethylation of miR-34a promoter and increased miR-34a expression, which in turn sensitized MIBC cells to cisplatin and decreased the tumorigenicity and proliferation of cancer cells that by reducing the production of CD44."
For more information on this research see: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy. Molecular Cancer, 2014;13():1-11. Molecular Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Molecular Cancer - www.molecular-cancer.com)
Our news correspondents report that additional information may be obtained by contacting H. Li, Anhui Medical University, Affiliated Hosp 1, Dept. of Urol, Hefei 230022, Anhui, People's Republic of China. Additional authors for this research include G. Yu, R.L. Shi, B. Lang, X.G. Chen, D. Xia, H.B. Xiao, X.L. Guo, W. Guan, Z.Q. Ye, W. Xiao and H. Xu (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Anhui, Drugs, Genetics, Oncology, Cisplatin, Chemotherapy, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds, Cancer Gene Therapy, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC